Seelos Therapeutics Future Growth
Future criteria checks 0/6
Seelos Therapeutics's revenue is forecast to decline at 128.2% per annum while its annual earnings are expected to grow at 23.3% per year. EPS is expected to grow by 129.5% per annum.
Key information
23.3%
Earnings growth rate
129.5%
EPS growth rate
Pharmaceuticals earnings growth | 20.1% |
Revenue growth rate | -128.2% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 22 Jan 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2024 | N/A | -36 | N/A | N/A | 1 |
12/31/2023 | 2 | -39 | N/A | N/A | 1 |
9/30/2023 | 2 | -51 | -35 | -35 | N/A |
6/30/2023 | 1 | -81 | -40 | -40 | N/A |
3/31/2023 | 1 | -73 | -55 | -55 | N/A |
12/31/2022 | N/A | -74 | -62 | -62 | N/A |
9/30/2022 | N/A | -82 | -67 | -67 | N/A |
6/30/2022 | N/A | -73 | -66 | -66 | N/A |
3/31/2022 | N/A | -61 | -55 | -55 | N/A |
12/31/2021 | N/A | -66 | -49 | -49 | N/A |
9/30/2021 | N/A | -45 | -34 | -34 | N/A |
6/30/2021 | N/A | -39 | -28 | -28 | N/A |
3/31/2021 | N/A | -33 | -26 | -26 | N/A |
12/31/2020 | N/A | -19 | -21 | -21 | N/A |
9/30/2020 | N/A | -23 | -23 | -23 | N/A |
6/30/2020 | 0 | -22 | -21 | -21 | N/A |
3/31/2020 | 0 | -21 | -18 | -18 | N/A |
12/31/2019 | 0 | -51 | -19 | -19 | N/A |
9/30/2019 | 0 | -42 | -15 | -15 | N/A |
6/30/2019 | N/A | -40 | -12 | -12 | N/A |
3/31/2019 | N/A | -38 | -9 | -9 | N/A |
12/31/2018 | N/A | -3 | -2 | -2 | N/A |
9/30/2018 | N/A | -3 | -1 | -1 | N/A |
6/30/2018 | N/A | -2 | -1 | -1 | N/A |
3/31/2018 | N/A | -2 | -1 | -1 | N/A |
12/31/2017 | N/A | -12 | -10 | -10 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NXE is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NXE is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NXE is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NXE's revenue is expected to decline over the next 3 years (-128.2% per year).
High Growth Revenue: NXE's revenue is forecast to decline over the next 3 years (-128.2% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NXE's Return on Equity is forecast to be high in 3 years time